Brief: Spero Therapeutics Announces First Quarter 2023 Operating Results And Provides A Business Update
11/05/2023 21:51
Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES FIRST QUARTER 2023 OPERATING
RESULTS AND PROVIDES A BUSINESS UPDATE
* SPERO THERAPEUTICS - PHASE 2 TRIAL OF SPR720 IN
NONTUBERCULOUS
MYCOBACTERIAL PULMONARY DISEASE ON TRACK FOR TOP LINE DATA
READOUT IN 1H 2024
* SPERO THERAPEUTICS INC - AS OF MARCH 31, 2023, CO HAD CASH
AND
CASH EQUIVALENTS OF $96.3 MILLION
* SPERO - SEES CASH & CASH EQUIVALENTS, TOGETHER WITH OTHER
NON-DILUTIVE FUNDING COMMITMENTS, SUFFICIENT TO FUND OPERATING
EXPENSES & CAPEX BEYOND 2024
* SPERO THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.25
Source text for Eikon: ID:nGNX3QRzrv
Further company coverage: SPRO.O
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)